No Data
No Data
No Data
Adikon Holdings successfully listed in an IPO in Hong Kong, co-endorsed by Morgan Stanley and Furui
On June 30, 2023, ADICON Holdings Limited (“Adikon Holdings” for short) (09860.HK) from Hangzhou, Zhejiang, was successfully listed on the main board of the Hong Kong Stock Exchange. Adikon Holdings, founded in 2004, is an independent medical laboratory operated by a national chain. It has set up more than 32 medical laboratories nationwide and is one of the top three independent medical laboratory service providers in China. As of December 31, 2022, Adikon Holdings' testing portfolio includes approximately 4,000 medical diagnostic tests
Cali Biotech B, submits a prospectus for IPO listing in Hong Kong, exclusively endorsed by Agricultural Bank International
On June 28, 2023, Jiali Biotechnology Co., Ltd. from Shenzhen, Guangdong CALI BIOSCIENCES CO., LTD.. (“Callie Biotech” for short) submitted a prospectus to the Hong Kong Stock Exchange to be listed on the Hong Kong Main Board.
Cali Biotech once again submitted a prospectus to be listed on the Hong Kong stock market
Li Li of Leju Finance once again submitted listing application materials on the Hong Kong Stock Exchange on June 28, Jiali Biotechnology Co., Ltd. (“Cali Biotech”) once again submitted its listing application materials on the Hong Kong Stock Exchange. According to information, Callie Biotech submitted a statement on the Hong Kong Stock Exchange on January 31, 2022.
Callix Biotech this past year: star shareholders joined, increased commercialization certainty
Since the beginning of the year, it has become a market consensus that the overall valuation of the Hong Kong biomedical sector has gradually bottomed out in the midst of continuous fluctuations, but considering that policies, fundamentals, and liquidity are all expected to show an improvement trend in the second half of the year, the current innovative drug sector, especially differentiated innovative pharmaceutical companies with faster demand growth and a better competitive pattern, may welcome opportunities on the left side.
No Data
No Data